Novartis Boston Consulting Group Matrix

Pluvicto, a targeted radioligand therapy for prostate cancer, is a significant growth driver for Novartis. Its Q2 2025 sales hit $454 million, marking a substantial 22% jump from the previous quarter, underscoring its strong market momentum.

The FDA's approval in April 2024 for use before chemotherapy has broadened Pluvicto's accessibility, allowing Novartis to pursue its integration into earlier treatment stages. This strategic move is expected to further fuel its market penetration.

With projected peak sales exceeding $5 billion, Pluvicto is positioned as a star performer within Novartis' oncology pipeline, reflecting its therapeutic innovation and commercial success.

Novartis' "Stars" in the BCG Matrix represent products with high market share and high growth potential, demanding significant investment to maintain their leading positions. These are the company's current growth engines, poised for continued success.

Kisqali, an oncology therapy, saw its sales reach $1.177 billion in Q2 2025, a 64% constant currency increase, driven by expanded approvals. Leqvio, a cholesterol-lowering medication, achieved $257 million in Q1 2025 sales, up 70%, due to its innovative technology. Pluvicto, a prostate cancer therapy, reported $454 million in Q2 2025 sales, a 22% increase, benefiting from earlier treatment approvals and projected peak sales over $5 billion. Kesimpta, for multiple sclerosis, posted $899 million in Q1 2025 sales, a 49% rise in 2024, attributed to its convenient administration.

Promacta/Revolade, a key treatment for thrombocytopenia, demonstrated robust performance with $2.216 billion in sales during 2024. This drug has consistently been a significant revenue driver for Novartis, underscoring its importance within the company's portfolio.

Despite the anticipation of potential U.S. generic competition in mid-2025, Novartis is actively pursuing strategies to extend Promacta/Revolade's market life and maximize its value. This focus reflects the drug's established position and its ongoing contribution to the company's financial health.

These products represent Novartis's established, high-performing assets that generate substantial and consistent revenue with minimal investment. Their strong market share and continued demand solidify their role as dependable cash cows, funding innovation and growth in other areas of the company's portfolio.

The Galvus Group, primarily featuring vildagliptin, experienced a significant sales downturn in 2024, dropping by 13% to $602 million. This consistent decline points to a market that has matured and is facing increased pressure, likely from generic alternatives, leading to diminishing returns for Novartis.

This performance places Galvus firmly in the Dogs category of the BCG Matrix. The products are generating low growth and low market share, suggesting they are becoming less profitable and could be tying up valuable resources that could be better allocated to more promising ventures within Novartis’s portfolio.

Novartis's 'Dogs' represent products with low market share and low growth potential, often facing intense competition or market saturation. These products, while still generating revenue, are typically not strategic priorities for significant investment. Companies often consider divesting or repositioning these assets to focus resources on more promising areas.

In 2024, several Novartis products exemplified this 'Dog' classification. Tasigna, a leukemia medication, saw its global revenue drop by 8% to $1.7 billion, facing imminent generic competition. Similarly, Lucentis, an ophthalmic injection, experienced a sharp 29% sales decline to $1.044 billion, indicating a weakening market position.

The Galvus Group, primarily vildagliptin, declined 13% to $602 million, suggesting a mature market with increasing pressure. The Diovan Group, a cardiovascular treatment, fell 4% to $590 million due to generic competition in a saturated market. Lastly, the Sandostatin Group, with octreotide, dipped 3% to $1.279 billion in a low-growth market, signaling a loss of competitive edge.

OAV101 IT, Novartis's next-generation gene therapy for spinal muscular atrophy (SMA) and a follow-up to Zolgensma, is positioned as a significant growth driver. Pivotal trial results are anticipated before the close of 2024, with expectations of a more straightforward administration compared to its predecessor.

This innovative therapy holds multibillion-dollar peak sales potential, reflecting its novel approach within the gene therapy landscape. The current market share is low, but its high growth prospects firmly place OAV101 IT in the 'Question Mark' category of the BCG matrix.

Significant investment will be crucial to navigate clinical development, regulatory approvals, and market penetration, thereby unlocking its substantial commercial promise and solidifying its position in the SMA treatment market.

Question Marks in Novartis' portfolio represent products with high growth potential but currently low market share, requiring significant investment to capture market share. These assets, like Remibrutinib and Pelacarsen, are in early stages of development or market entry. Their success hinges on continued investment in clinical trials, regulatory approvals, and market penetration strategies to transition them into Star performers.